Phase I/II, Randomized Double-Blinded, Placebo-Controlled Study Designed To Evaluate Safety, Tolerability of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck.

Trial Profile

Phase I/II, Randomized Double-Blinded, Placebo-Controlled Study Designed To Evaluate Safety, Tolerability of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs T-cell vaccine AlloVax (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immunovative Therapies
  • Most Recent Events

    • 07 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
    • 07 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.
    • 26 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top